Requires managed care providers and the medical assistance program shall cover prescription drugs approved by the federal food and drug administration for chronic weight management in adults with obesity with at least one weight-related condition.
Impact
The bill is expected to have a significant impact on state laws regarding health coverage, particularly by expanding the range of treatments for obesity that must be covered under managed care plans. By doing so, it aligns New York with broader healthcare goals of improving public health and reducing the burden of obesity on the healthcare system. Proponents of the bill argue that this change will lead to better health outcomes for individuals affected by obesity, allowing them to access medications that can support their weight management efforts effectively.
Summary
Bill A10820 proposes an amendment to the social services law to ensure that managed care providers and the medical assistance program are mandated to cover prescription drugs that have been approved by the FDA for chronic weight management in adults who are obese and have at least one weight-related condition. This legislative measure aims to improve access to necessary medications for individuals struggling with obesity, recognizing it as a significant health issue that can lead to various comorbidities.
Contention
However, there may be points of contention surrounding the bill’s implementation. Critics might argue about the potential financial implications for managed care providers and whether this could lead to increased premiums for consumers. Additionally, discussions could arise concerning the definition of 'obesity' and the criteria for coverage, which might affect who qualifies for the benefits under this bill. There could also be debates on the efficacy of weight management drugs and the long-term implications of subsidizing these medications.
Same As
Requires managed care providers and the medical assistance program shall cover prescription drugs approved by the federal food and drug administration for chronic weight management in adults with obesity with at least one weight-related condition.
Requires managed care providers and the medical assistance program shall cover prescription drugs approved by the federal food and drug administration for chronic weight management in adults with obesity with at least one weight-related condition.
Requires insurers to cover the substitution of a brand name prescription drug when the federal food and drug administration has declared that there is a supply issue with a generic drug.
Requires insurance companies, medical expense indemnity corporations, hospital service corporations, health service corporations and medical assistance programs to provide coverage for prescribed antiviral therapeutics approved by the food and drug administration for the treatment of COVID-19 at no cost to the patient.
Enacts the "foreign drug transparency act" to provide information on the origin, manufacture and distribution of prescription drugs; requires a pharmacy benefit manager to maintain, and make available to pharmacies, health plans, and patients upon request, supply chain information for prescription drugs covered under its network.
Enacts the "foreign drug transparency act" to provide information on the origin, manufacture and distribution of prescription drugs; requires a pharmacy benefit manager to maintain, and make available to pharmacies, health plans, and patients upon request, supply chain information for prescription drugs covered under its network.
Maryland Medical Assistance Program and Health Insurance - Coverage and Utilization Review - Drugs Reviewed by the Prescription Drug Affordability Board